Sulfonamide inhibitors of aspartyl protease

Details Sulfonamide inhibitors of aspartyl protease Sulfonamide inhibitors of aspartyl protease

2006-04-19

2009-10-27

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S126000

Reexamination Certificate

active

07608632

ABSTRACT:
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

REFERENCES:
patent: 3743722 (1973-07-01), Mohrs et al.
patent: 4330542 (1982-05-01), Descamps et al.
patent: 4629724 (1986-12-01), Ryono et al.
patent: 5196438 (1993-03-01), Martin et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 3542567 (1986-06-01), None
patent: 0 022 118 (1981-01-01), None
patent: 0 181 071 (1986-03-01), None
patent: 0 264 795 (1988-04-01), None
patent: 0 346 847 (1989-12-01), None
patent: 0 364 804 (1990-04-01), None
patent: 0 468 641 (1992-01-01), None
patent: 0 486 948 (1992-05-01), None
patent: 0 541 168 (1993-05-01), None
patent: 2167759 (1986-06-01), None
patent: 2200115 (1988-07-01), None
patent: 59046252 (1984-03-01), None
patent: 59048449 (1984-03-01), None
patent: 61071830 (1986-04-01), None
patent: WO 90/07329 (1990-07-01), None
patent: WO 91/00725 (1991-01-01), None
patent: WO 91/18866 (1991-12-01), None
patent: WO 92/08688 (1992-05-01), None
patent: WO 92/08698 (1992-05-01), None
patent: WO 92/08699 (1992-05-01), None
patent: WO 92/08700 (1992-05-01), None
patent: WO 92/08701 (1992-05-01), None
patent: WO 92/17176 (1992-10-01), None
patent: WO 93/23368 (1993-11-01), None
patent: WO 93/23379 (1993-11-01), None
patent: WO 93/23388 (1993-11-01), None
patent: WO 94/04491 (1994-03-01), None
patent: WO 94/04492 (1994-03-01), None
patent: WO 94/04493 (1994-03-01), None
patent: WO 94/10134 (1994-05-01), None
patent: WO 94/10136 (1994-05-01), None
patent: WO 94/18192 (1994-08-01), None
patent: WO 94/19322 (1994-09-01), None
Obach R. S., Drug-drug interactions; An important negative attribute in drugs, Drugs of Today, 39(5), 301-38, (2003).
Craig et al., Antiviral Chemistry & Chemotherapy (1990), 4(3), 161-166.
R.D. Bindal et al., “Ab Initio Calculations on N-Methylmethanesulfonamide and Methyl Methanesulfonate for the Development of Force Field Torsional Parameters and Their Use in the Conformational Analysis of Some Novel Estrogens”,J. Am. Chem. Soc., 112, pp. 7861-7868 (1990).
R. Bone et al., “X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2Symmetry”,J. Am. Chem. Soc., 113, pp. 9382-9384 (1991).
R.F. Borch et al., “The Cyanohydridoborate Anion as a Selective Reducing Agent”,J. Am. Chem. Soc., 93, pp. 2897-2904 (1971).
J.C. Craig et al., “Antiviral Synergy Between Inhibitors of HIV Proteinase and Reverse Transcriptase”,Antiviral Chem. and Chemotherapy, 4(3), pp. 161-166 (1990).
S. Crawford et al., “A Deletion Mutation in the 5′ Part of the pol Gene of Moloney Murine Leukemia Virus Blocks Proteolytic Processing of the gag and pol Polyproteins”,J. Virol., 53, pp. 899-907 (1985).
M. Cushman et al., “Delvelopment of Methodology for the Synthesis of Stereochemically Pure Pheψ[CH2N]Pro Linkages in HIV Protease Inhibitors”,J. Org. Chem., 56, pp. 4161-4167 (1991).
D.S. Dhanoa et al., “The Synthesis of Potent Macrocyclic Renin Inhibitors”,Tetrahedron Lett., 33, pp. 1725-1728 (1992).
G.B. Dreyer et al., “Hydroxyethylene Isostere Inhibitors of Human Immunodeficiency Virus-1 Protease: Structure-Activity Analysis Using Enzyme Kinetics, X-ray Crystallography, and Infected T-Cell Assays”,Biochemistry, 31, pp. 6646-6659 (1992).
B.E. Evans et al., “A Stereocontrolled Synthesis of Hydroxyethylene Dipeptide lsosteres Using Novel, Chiral Aminoalkyl Epoxides and γ-(Aminoalkyl) γ-Lactones”,J. Org. Chem., 50, pp. 4615-4625 (1985).
G.A. Flynn et al., “An Acyl-Iminium Ion Cyclization Route to a Novel Conformationally Restricted Dipeptide Mimic: Applications to Angiotensin-Converting Enzyme Inhibition”,J. Am. Chem. Soc., 109, pp. 7914-7915 (1989).
G. Fontenot et al., “PCR Amplification of HIV-1 Proteinase Sequences Directly from Lab Isolates Allows Determination of Five Conserved Domains”,Virology, 190, pp. 1-10 (1992).
P.G. Gassman and T.L. Guggenheim, “Opening of Epoxides with Trimethylsilyl Cyanide to Produce β-Amino Alcohols”,J. Am. Chem. Soc., 104, pp. 5849-5850 (1982).
E.E. Gilbert, “Recent Developments in Preparative Sulfonation and Sulfation”,Synthesis, 1969, pp. 3-10 (1969).
A. Goldblum, “Modulation of the Affinity of Aspartic Proteases by the Mutated Residues in Active Site Models”,FEBS, 261, pp. 241-244 (1990).
D. Grobelny et al., “Selective Phosphinate Transition-State Analogue Inhibitors of the Protease of Human Immunodeficiency Virus”,Biochem. Biophys. Res. Commun., 169, pp. 1111-1116 (1990).
G.D. Hartman et al., “4-Substituted Thiophene- and Furan-2-sulfonamides as Topical Carbonic Anhydrase Inhibitors”J. Med. Chem., 35, pp. 3822-3831 (1992).
J.R. Huff, “HIV Protease: A Novel Chemotherapeutic Target for AIDS”,Journal of Medicinal Chemistry, 34(8), pp. 2305-2314 (1991).
K.Y. Hui et al., “A Rational Approach in the Search for Potent Inhibitors Against HIV Proteinase”,FASEB, 5, pp. 2606-2610 (1991).
N. E. Kohl et al., “Active HIV Protease Is Required for Viral Infectivity”,Proc. Natl. Acad. Sci. USA, 85, pp. 4686-4690 (1988).
X. Lin et al., “Enzymic Activities of Two-Chain Pepsinogen, Two-Chain Pepsin, and the Amino-Terminal Lobe of Pepsinogen”,J. Biol. Chem., 267(24), pp. 17257-17263 (1992).
K.P. Manfredi et al., “Examination of HIV-1 Protease Secondary Structure Specificity Using Conformationally Constrained Inhibitors”,J. Med. Chem., 34, pp. 3395-3399 (1991) .
F.R. Marshall, “Computer-Aided Drug Design”,Ann. Ref. Pharmacol. Toxicol., 27. pp. 193-213 (1987).
J.A. Martin, “Recent Advances in the Design of HIV Proteinase Inhibitors”,Antiviral Research, 17, pp. 265-278 (1992).
T.D. Meek et al., “Inhibition of HIV-1 Protease in Infected T-Lymphocytes by Synthetic Peptide Analogues”,Nature, 343, pp. 90-92 (1990).
M. Miller et al., “Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 < Resolution”,Science, 246, pp. 1149-1152 (1989).
M. Miller et al., “Crystal Structure of a Retroviral Protease Proves Relationship to Aspartic Protease Family”,Nature, 337, pp. 576-579 (1989).
H. Mitsuya and S. Broder, “Inhibition of the in vitro Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphoadenopathy-Associated Virus (HTLV-III/LAV) by 2′,3′-Dideoxynucleosides”,Proc. Natl. Acad. Sci. USA, 83, pp. 1911-1915 (1986).
K.H.M. Murthy et al., “Crystal Structures at 2.2-< Resolution of Hydroxyethylene-Based Inhibitors Bound to Human Immunodeficiency Virus Type 1 Protease Show That the Inhibitors Are Present in Two Distinct Orientations”,J. Biol. Chem., 267, pp. 22770-22778 (1992).
J.B. Nichols et al., “A Molecular Mechanics Valence Force Field for Sulfonamides Derived by ab initio Methods”,J. Phys. Chem., 95, pp 9803-9811 (1991).
L.E. Overman and L.A. Flippin, “Facile Aminolysis of Epoxides with Diethylaluminum Amides”, Tetrahedron Letters, 195, pp. 195-198 (1981).
J. Palca, “Shooting at a New HIV Target”,Science, 247, p. 410 (1990).
L.H. Pearl et al., “A Structural Model for the Retroviral Proteases”,N

Affiliated with

Also associated with

Rating

Sulfonamide inhibitors of aspartyl protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide inhibitors of aspartyl protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide inhibitors of aspartyl protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4111103